

## Influenza B Virus, B/Malaysia/2506/2004

### Catalog No. NR-12280

This reagent is the property of the U.S. Government.

### For research use only. Not for use in humans.

#### Contributor:

National Institute of Allergy and Infectious Diseases (NIAID),  
National Institutes of Health (NIH), Bethesda, Maryland, USA

#### Manufacturer:

BEI Resources

#### Product Description:

Virus Classification: *Orthomyxoviridae, Influenzavirus B*

Species: Influenza B virus

Strain/Isolate: B/Malaysia/2506/2004

Original Source: Influenza B virus, B/Malaysia/2506/2004, was isolated on June 12, 2004, from a human nasal swab in Malaysia.<sup>1</sup> Following isolation, this strain was passaged in eggs at the CDC, followed by two egg passages at Baylor College of Medicine prior to deposition.

Comments: Influenza B/Malaysia/2506/04-like viruses have been recommended for use as part of trivalent influenza vaccines worldwide from 2006-2008.<sup>2,3,4,5</sup> The CDC deposit of Influenza B/Malaysia/2506/04 is available as NR-9723. Sequence information is available for Influenza B virus, B/Malaysia/2506/2004 at the [Bacterial and Viral Bioinformatics Resource Center](#).

#### Material Provided:

Each vial contains approximately 1.0 mL of pooled allantoic fluid from specific pathogen-free (SPF) embryonated chicken eggs infected with influenza B virus, B/Malaysia/2506/2004.

Note: If homogeneity is required for your intended use, please purify prior to initiating work.

#### Packaging/Storage:

NR-12280 was packaged aseptically in plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

#### Growth Conditions:

Host: 9- to 11-day-old SPF embryonated chicken eggs

Infection: Embryonated chicken eggs must be candled to confirm viability prior to inoculation

Incubation: 2 days at 33°C in a humidified chamber

Effect: Hemagglutination activity using allantoic fluid from infected embryonated chicken eggs and chicken red blood cells

#### Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Influenza B Virus, B/Malaysia/2506/2004, NR-12280."

#### Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in Microbiological and Biomedical Laboratories \(BMBL\)](#). 6th ed. Washington, DC: U.S. Government Printing Office, 2020.

#### Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure the authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

#### Use Restrictions:

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before the first commercial sale.

#### References:

1. Klimov, A., Personal Communication.
2. World Health Organization. "Recommended Composition of Influenza Virus Vaccines for Use in the 2006 Influenza Season." *Wkly. Epidemiol. Rec.* 80 (2005): 342-347. PubMed: 16240985.

3. World Health Organization. "Recommended Composition of Influenza Virus Vaccines for Use in the 2006-2007 Influenza Season." Wkly. Epidemiol. Rec. 81 (2006): 82-86. PubMed: 16671218.
4. World Health Organization. "Recommended Composition of Influenza Virus Vaccines for Use in the 2007 Influenza Season." Wkly. Epidemiol. Rec. 81 (2006): 390-395. PubMed: 17039626.
5. World Health Organization. "Recommended Composition of Influenza Virus Vaccines for Use in the 2007-2008 Influenza Season." Wkly. Epidemiol. Rec. 82 (2007): 69-74. PubMed: 17333570.
6. Daum, L. T., et al. "Molecular Analysis of Isolates from Influenza B Outbreaks in the U.S. and Nepal, 2005." Arch. Virol. 151 (2006): 1863-1874. PubMed: 16736092.
7. O'Brien, K. and I. G. Barr. "Annual Report of the National Influenza Surveillance Scheme, 2006." Commun. Dis. Intell. 31 (2007): 167-179. PubMed: 17724991.

ATCC® is a trademark of the American Type Culture Collection.

